Literature DB >> 18924210

Decreased IL-10 and IL-13 production and increased CD44hi T cell recruitment contribute to Leishmania major immunity induced by non-persistent parasites.

Lukasz Kedzierski1, Joan M Curtis, Peter C Doherty, Emanuela Handman, Katherine Kedzierska.   

Abstract

Leishmaniasis is currently classified as category 1 disease, i.e. emerging and uncontrolled. Since the importance of persistent infection for maintaining an effective long-lasting protective response is controversial, the present study asks whether immunisation with non-persistent parasites leads to protection against Leishmania infection and to the recruitment of T cells of a specific phenotype. Our study shows that vaccination of susceptible BALB/c mice with live Leishmania major phosphomannomutase-deficient parasites, which are avirulent and non-persistent in vivo, leads to protection against infection. Immunisation with phosphomannomutase-deficient parasites neither leads to differences in IFN-gamma, IL-12, IL-4 production nor alters the expression of effector and memory markers, including CD62L, IL-7Ralpha and IL-2Ralpha, when compared with unvaccinated controls. Observed protection is due to the ability of vaccinated animals to suppress early IL-10 and IL-13 production and to recruit a higher number of antigen-experienced CD44hiCD4+ and CD44hiCD8+ T cells into draining LN following infection. Thus, expansion of T-cell numbers and their rapid recruitment to LN upon infection as well as the restriction of IL-13 and IL-10 production leading to high IFN-gamma/IL-10 ratio play an important role in protection against Leishmania affecting the outcome of the disease in favour of the host.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18924210     DOI: 10.1002/eji.200838423

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  14 in total

1.  Leishmania-Derived Trimannose Modulates the Inflammatory Response To Significantly Reduce Leishmania major-Induced Lesions.

Authors:  Tara L Grinnage-Pulley; Daniel E K Kabotso; Chelsea L Rintelmann; Rajarshi Roychoudhury; Robert G Schaut; Angela J Toepp; Katherine N Gibson-Corley; Molly Parrish; Nicola L B Pohl; Christine A Petersen
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

2.  Leishmaniasis Vaccine: Where are We Today?

Authors:  Lukasz Kedzierski
Journal:  J Glob Infect Dis       Date:  2010-05

Review 3.  Whole blood assay and visceral leishmaniasis: Challenges and promises.

Authors:  Om Prakash Singh; Shyam Sundar
Journal:  Immunobiology       Date:  2014-01-31       Impact factor: 3.144

4.  T cell-derived IL-10 determines leishmaniasis disease outcome and is suppressed by a dendritic cell based vaccine.

Authors:  Tobias Schwarz; Katharina A Remer; Wiebke Nahrendorf; Anita Masic; Lisa Siewe; Werner Müller; Axel Roers; Heidrun Moll
Journal:  PLoS Pathog       Date:  2013-06-27       Impact factor: 6.823

5.  Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites.

Authors:  Angamuthu Selvapandiyan; Ranadhir Dey; Sreenivas Gannavaram; Ines Lakhal-Naouar; Robert Duncan; Poonam Salotra; Hira L Nakhasi
Journal:  J Trop Med       Date:  2011-09-06

6.  Induction of protective CD4+ T cell-mediated immunity by a Leishmania peptide delivered in recombinant influenza viruses.

Authors:  Katherine Kedzierska; Joan M Curtis; Sophie A Valkenburg; Lauren A Hatton; Hiu Kiu; Peter C Doherty; Lukasz Kedzierski
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

7.  Protective immunity and vaccination against cutaneous leishmaniasis.

Authors:  Ifeoma Okwor; Zhirong Mou; Dong Liu; Jude Uzonna
Journal:  Front Immunol       Date:  2012-05-29       Impact factor: 7.561

8.  Adjuvants for Leishmania vaccines: from models to clinical application.

Authors:  Vanitha S Raman; Malcolm S Duthie; Christopher B Fox; Greg Matlashewski; Steven G Reed
Journal:  Front Immunol       Date:  2012-06-11       Impact factor: 7.561

9.  Effects of long-term dietary nitrate supplementation in mice.

Authors:  Michael P Hezel; Ming Liu; Tomas A Schiffer; Filip J Larsen; Antonio Checa; Craig E Wheelock; Mattias Carlström; Jon O Lundberg; Eddie Weitzberg
Journal:  Redox Biol       Date:  2015-05-29       Impact factor: 11.799

10.  Development of Leishmania vaccines: predicting the future from past and present experience.

Authors:  Joshua Muli Mutiso; John Chege Macharia; Maria Ndunge Kiio; James Maina Ichagichu; Hitler Rikoi; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.